NCT01180959 2022-11-07
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
4 trialsNCT00881751 2017-09-11
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Medical University of South Carolina
Phase 2 Completed
NCT00987766 2017-07-02
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT00293436 2012-09-17
Celecoxib and Erlotinib in Treating Patients With Liver Cancer
University of California, San Francisco
Phase 1/2 Withdrawn